Enliven Therapeutics ELVN Change in AP
Change in AP at other companies
Other financials
Where this comes from
Reported directly by Enliven Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsPayable.
The official record: Enliven Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Enliven Therapeutics's change in ap.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Enliven Therapeutics's change in AP?
- Enliven Therapeutics (ELVN) reported change in AP of -$519K in Q1 2026.
- How has Enliven Therapeutics's change in AP changed year-over-year?
- Enliven Therapeutics's change in AP decreased by 335.9% year-over-year, from $220K to -$519K.
- What is the long-term trend for Enliven Therapeutics's change in AP?
- Over 2 years (2022 to 2025), Enliven Therapeutics's change in AP has grown at a 41.0% compound annual growth rate (CAGR), from $411K to $817K.
- What does change in AP mean?
- Increase or decrease in amounts owed to suppliers — a key working capital component affecting operating cash flow.